Roth Mkm Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Roth Mkm began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $11.00 price target on the stock.

Other analysts have also issued reports about the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Northland Securities initiated coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Finally, Oppenheimer initiated coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.25.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $4.50 on Monday. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42. The business has a fifty day moving average of $4.39 and a 200-day moving average of $5.86.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million during the quarter. As a group, research analysts forecast that TriSalus Life Sciences will post -1.5 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the acquisition, the chief executive officer now owns 377,382 shares in the company, valued at approximately $1,962,386.40. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences during the second quarter worth about $240,000. Duquesne Family Office LLC boosted its holdings in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares during the last quarter. Finally, Highbridge Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $1,184,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.